MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

Home・Aandelen Lijst・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Gesloten

SectorGezondheidszorg

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	-0.05% downside

Mirati Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 apr 2026, 18:16 UTC

Belangrijke Nieuwsgebeurtenissen

Bank of Mexico Cautious After Interest-Rate Cut, Minutes Show

9 apr 2026, 23:44 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

9 apr 2026, 23:34 UTC

Marktinformatie

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

9 apr 2026, 23:14 UTC

Marktinformatie

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

9 apr 2026, 23:14 UTC

Marktinformatie

Global Equities Roundup: Market Talk

9 apr 2026, 23:07 UTC

Marktinformatie

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

9 apr 2026, 22:54 UTC

Marktinformatie

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

9 apr 2026, 22:31 UTC

Belangrijke Nieuwsgebeurtenissen

Trump on Truth Social: 'That Is Not the Agreement We Have!'

9 apr 2026, 22:31 UTC

Belangrijke Nieuwsgebeurtenissen

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

9 apr 2026, 20:57 UTC

Belangrijke Nieuwsgebeurtenissen

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

9 apr 2026, 20:55 UTC

Winsten

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

9 apr 2026, 20:55 UTC

Winsten

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

9 apr 2026, 20:55 UTC

Winsten

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

9 apr 2026, 20:50 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

9 apr 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 apr 2026, 20:40 UTC

Acquisities, Fusies, Overnames

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

9 apr 2026, 20:39 UTC

Acquisities, Fusies, Overnames

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

9 apr 2026, 20:39 UTC

Acquisities, Fusies, Overnames

Rowan Digital Infrastructure Announces Strategic Recapitalization

9 apr 2026, 20:25 UTC

Acquisities, Fusies, Overnames

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

9 apr 2026, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

9 apr 2026, 19:30 UTC

Belangrijke Nieuwsgebeurtenissen

How Digital Currencies Have Helped Iran -- WSJ

9 apr 2026, 19:25 UTC

Marktinformatie

Crude Futures End Volatile Session Higher -- Market Talk

9 apr 2026, 19:16 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

9 apr 2026, 19:16 UTC

Marktinformatie

Livestock Mixed After USDA Cuts Production Outlook -- Market Talk

9 apr 2026, 18:55 UTC

Marktinformatie

Global Energy Roundup: Market Talk

9 apr 2026, 18:55 UTC

Marktinformatie

U.S. Natural Gas Futures Fall On Weather, Storage Data -- Market Talk

9 apr 2026, 18:50 UTC

Acquisities, Fusies, Overnames

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

9 apr 2026, 18:44 UTC

Marktinformatie

Global Equities Roundup: Market Talk

9 apr 2026, 18:44 UTC

Marktinformatie

Barrick's Former CEO Paid Severance Package of More Than $21 Million -- Market Talk

9 apr 2026, 18:20 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Pulls Back As Israel to Negotiate With Lebanon -- Market Talk

Peer Vergelijking

Prijswijziging

Mirati Therapeutics Inc Prognose

Koersdoel

By TipRanks

-0.05% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 58.67 USD -0.05%

Hoogste 59 USD

Laagste 58 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Mirati Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Mirati Therapeutics Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

EBITDA

Operationele winst

Over Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.